In recent years, we have witnessed the propagation and marketing of numerous diagnostic tests capable of detecting, in the urine of patients, the presence of urothelial tumor markers. None of the different markers studied to date, no one has been able to meet all the requirements of the ideal marker. We present and discuss below the results reported in the literature of two tests approved by the Food and Drug Administration [ImmunoCyt/uCyt+ and Fluorescence In Situ Hybridisation (FISH)], which have been commercially available for about 10 years.
LokeshwarV.B., HabuchiT., GrossmanH.B.Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology2005; 66(6 Suppl. 1): 35–63.
4.
GoebellP.J., GroshenS.L., Schmitz-DrägerB.J.Guidelines for development of diagnostic markers in bladder cancer. World J Urol2008; 26(1): 5–11.
5.
FradetY., LockhardC.Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. Can J Urol1997; 4(3): 400–405.
6.
FeilG., ZumbrägelA., Päulgen-NeldeH.J.Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder. Anticancer Res2003; 23(2A): 963–967.
7.
VriesemaJ.L., AtsmaF., KiemeneyL.A., PeelenW.P., WitjesJ.A., SchalkenJ.A.Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology2001; 58(3): 367–371.
8.
ComplojE., MianC., Ambrosini-SpaltroA.uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: An update on 7422 analyses. Cancer Cytopathol2013. doi: 10.1002/cncy.21287.
9.
PfisterC., ChautardD., DevonecM.Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol2003; 169(3): 921–924.
10.
MessingE.M., TeotL., KormanH.Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J Urol2005; 174(4 Pt. 1): 1238–1241.
11.
TêtuB., TiguertR., HarelF., FradetY.ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol2005; 18(1): 83–89.
12.
MianC., LoddeM., ComplojE.The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder. Anticancer Res2005; 25(5): 3641–3644.
13.
LoddeM., MianC., ComplojE.uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology2006; 67(5): 950–954.
14.
OdishoA.Y., BerryA.B., AhmadA.E., CooperbergM.R., CarrollP.R., KonetyB.R.Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology. Eur Urol2013; 63(5): 936–940.
15.
TodenhöferT., HennenlotterJ., EsserM.Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma. Cancer Cytopathol2013; 121(5): 252–260.
16.
Schmitz-DrägerB.J., BeicheB., TirsarL.A., Schmitz-DrägerC., BismarckE., EbertT.Immunocytology in the assessment of patients with asymptomatic microhaematuria. Eur Urol2007; 51(6): 1582–1588.
17.
GibertiC., GalloF., SchenoneM., GenovaA.Early results of urothelial carcinoma screening in a risk population of coke workers: urothelial carcinoma among coke workers. Biomed Environ Sci2010; 23(4): 300–304.
18.
BangmaC.H., LoebS., BusstraM.Outcomes of a Bladder Cancer Screening Program Using Home Hematuria Testing and Molecular Markers. Eur Urol2013; 64(1): 41–47.
19.
TodenhöferT., HennenlotterJ., AufderklammS.Individual risk assessment in bladder cancer patients based on a multi-marker panel. J Cancer Res Clin Oncol2013; 139(1): 49–56.
20.
HorstmannM., TodenhöferT., HennenlotterJ.Influence of age on false positive rates of urine-based tumor markers. World J Urol2012.
21.
LiH.X., LiM., LiC.L.ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study. Anal Quant Cytol Histol2010; 32(1): 45–52.
22.
SoyuerI., SofikerimM., TokatF., SoyuerS., OzturkF.Which urine marker test provides more diagnostic value in conjunction with standard cytology-ImmunoCyt/uCyt+ or Cytokeratin 20 expression. Diagn Pathol2009; 4: 20.
23.
SullivanP.S., NooraieF., SanchezH.Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: a “split-sample” study. Cancer2009; 117(3): 167–173.
24.
MianC., MaierK., ComplojE.uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer2006; 108(1): 60–65.
25.
HautmannS., TomaM., Lorenzo GomezM.F.Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur Urol2004; 46(4): 466–471.
26.
LoddeM., MianC., NegriG.Effect of intravesical instillation on performance of uCYT+ test. Urology2004; 63(5): 878–881.
27.
TomaM.I., FriedrichM.G., HautmannS.H.Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol2004; 22(2): 145–149.
28.
MianC., LoddeM., ComplojE.Liquid-based cytology as a tool for the performance of uCyt+ and Urovysion Multicolour-FISH in the detection of urothelial carcinoma. Cytopathology2003; 14(6): 338–342.
29.
PiatonE., DanielL., VerrieleV.Improved detection of urothelial carcinomas with fluorescence immunocytochemistry (uCyt+ assay) and urinary cytology: results of a French Prospective Multicenter Study. Lab Invest2003; 83(6): 845–852.
30.
LoddeM., MianC., NegriG.Role of uCyt+ in the detection and surveillance of urothelial carcinoma. Urology2003; 61(1): 243–247.
31.
MianC., PychaA., WienerH., HaitelA., LoddeM., MarbergerM.Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol1999; 161(5): 1486–1489.
32.
SarosdyM.F., SchellhammerP., BokinskyG.Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol2002; 168(5): 1950–1954.
33.
MoonenP.M., MerkxG.F., PeelenP., KarthausH.F., SmeetsD.F., WitjesJ.A.UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol2007; 51(5): 1275–1280.
34.
BubendorfL., GrilliB.UroVysion multiprobe FISH in urinary cytology. Methods Mol Med2004; 97: 117–131.
35.
BubendorfL., GrilliB., SauterG., MihatschM.J., GasserT.C., DalquenP.Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol2001; 116(1): 79–86.
36.
MianC., LoddeM., ComplojE.Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. J Clin Pathol2006; 59(9): 984–987.
37.
CarawayN.P., KhannaA., FernandezR.L.Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study. Cancer Cytopathol2010; 118(5): 259–268.
38.
BanekS., SchwentnerC., TägerD.Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: Results from the UroScreen-Study. Urol Oncol2012.
39.
Denice SmithG., SangleN.A., WilsonA.A retrospective review of UroVysion fish interpretations over 8.6 years: a major shift in the patient test population. Diagn Cytopathol2013; 41(5): 437–447.
40.
PajorG., AlparD., KajtarB.Automated signal pattern evaluation of a bladder cancer specific multiprobe-fish assay applying a user-trainable workstation. Microsc Res Tech2012; 75(6): 814–820.
41.
XuC., ZengQ., HouJ.Utility of a modality combining FISH and cytology in upper tract urothelial carcinoma detection in voided urine samples of Chinese patients. Urology2011; 77(3): 636–641.
42.
MianC., MazzoleniG., VikolerS.Fluorescence in situ hybridisation in the diagnosis of upper urinary tract tumours. Eur Urol2010; 58(2): 288–292.
43.
AkkadT., BrunnerA., PallweinL.Fluorescence in situ hybridization for detecting upper urinary tract tumors–a preliminary report. Urology2007; 70(4): 753–757.
44.
ChenA.A., GrassoM.Is there a role for FISH in the management and surveillance of patients with upper tract transitional-cell carcinoma?J Endourol2008; 22(6): 1371–1374.
45.
JohannesJ.R., NelsonE., BibboM., BagleyD.H.Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance. J Urol2010; 184(3): 879–882.
46.
PychaA., LoddeM., ComplojE.Intermediate-risk urothelial carcinoma: an unresolved problem?Urology2004; 63(3): 472–475.
47.
MaffezziniM., CampodonicoF., CapponiG.Prognostic significance of fluorescent in situ hybridisation in the follow-up of non-muscle-invasive bladder cancer. Anticancer Res2010; 30(11): 4761–4765.
48.
KawauchiS., SakaiH., IkemotoK.9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology. Hum Pathol2009; 40(12): 1783–1789.
49.
KruegerS., MessF., BöhleA., FellerA.C.Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol2003; 23(1): 41–48.
50.
SavicS., ZlobecI., ThalmannG.N.The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guuerin therapy. Int J Cancer2009; 124(12): 2899–2904.
51.
WhitsonJ., BerryA., CarrollP., KonetyB.A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int2009; 104(3): 336–339.
